• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Diabetes Drugs and Cardioprotection: 8 Questions on Key Trials

Slideshow

Find out what you know about which diabetes drugs in which classes show CV protective properties and results of the trials that support their use.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
New Research Suggests Cardiac Events are Prevalent in Older Adults Hospitalized with RSV / Image credit: ©Kateryna Kon/AdobeStock

New Research Suggests Cardiac Events are Prevalent in Older Adults Hospitalized with RSV

April 16th 2024
Article

Nearly one-quarter of hospitalized adults aged 50 years and older with RSV experienced an acute cardiac event, according to results of a new study.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

"Inclisiran First" Strategy Leads to 60% Reduction in LDL-C vs 7% for Usual Care: VICTORIAN-INITIATE Findings

"Inclisiran First" Strategy Leads to 60% Reduction in LDL-C vs 7% for Usual Care: VICTORION-INITIATE Findings

April 6th 2024
Article

ACC. 24: A structured, systematic approach to lipid-lowering therapy in secondary prevention is needed to ensure targets are met and met swiftly, said researchers.

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

October 29th 2020
Podcast

Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.

T2D Remission via Lifestyle Intervention Reduces CVD, CKD Risk: Daily Dose / image credit: ©New Africa/AdobeStock

T2D Remission via Lifestyle Intervention Reduces CVD, CKD Risk: Daily Dose

April 4th 2024
Article

Your daily dose of the clinical news you may have missed.

image credit fish oil capsules: ©Sekphd/stock.adobe.com

Icosapent Ethyl Reduces MACE Across Range of Baseline Lp(a): REDUCE-IT Analysis

March 29th 2024
Article

ACC.24: Icosapent ethyl was associated with reduced rate of MACE at all baseline levels of Lp(a) in participants with elevated TG and at high risk for CVD.

© 2024 MJH Life Sciences

All rights reserved.